A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. [electronic resource]
Producer: 20051230Description: 1172-9 p. digitalISSN:- 0340-7004
- Animals
- Antibodies, Monoclonal -- genetics
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Complement Activation
- Complement System Proteins -- immunology
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Lymphoma, Non-Hodgkin -- drug therapy
- Mice
- Rituximab
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.